Beyond Air reports interim data results for LungFit GO pilot study » 08:1010/2010/20/21
Beyond Air announced…
Story temporarily locked.
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald » 07:0710/1510/15/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Alethia Young lowered the firm's price target on Incyte to $79 from $104 and keeps a Neutral rating on the shares. Young was "somewhat surprised" by the FDA adding a black box class warning to Opzelura, and the analyst is more cautious about a potentially slower uptake related to the class labelling, Young tells investors in a research note.
|Over a week ago|
Amazon shopping for long-range Boeing, Airbus cargo plans, Bloomberg reports » 12:5410/1310/13/21
AMZN, BA, EADSY, UPS, FDX
Amazon.com (AMZN) is…
Amazon.com (AMZN) is shopping for used long-range Boeing (BA) and Airbus (EADSY) cargo planes, Matt Day and Julie Johnsson of Bloomberg report, citing people familiar with the matter. Amazon is in the market for refurbished cargo versions of Boeing's 777-300ER and Airbus's A330-300 wide-body aircraft, sources told Bloomberg. Converted Boeing 777s would let Amazon directly import products from China and other countries, the sources said, which would step up the company's competition with UPS (UPS) and FedEx (FDX).
Katapult collaborates with Adobe to give consumers more ways to pay » 09:0610/1110/11/21
Katapult (KPLT) announced…
Katapult (KPLT) announced it has become an Accelerate partner in the Adobe (ADBE) Exchange Program. Adobe Commerce, powered by Magento, is an application for brands of all sizes and supports B2B, B2C, and hybrid use cases across more than 20 industries. Katapult's lease-purchase solution is available as an extension in the payment category of the Magento Marketplace and integrates with online platforms. As an Accelerate partner, Katapult and Adobe will engage in enhanced collaboration. Becoming an Accelerate partner means that Katapult's merchants utilizing Adobe Commerce or Magento Open Source will receive support and access to real-time data and partner offerings. "Upgrading our partnership with Adobe to the Accelerate tier furthers Katapult's goals of expanding our footprint in the fintech space. We are excited to add more value through our technology to merchants using Adobe Commerce and Magento Open Source," says Rolando De Gracia, Chief Commercial Officer of Katapult.
Hyatt opens IL Tornabuoni Hotel in Florence » 05:1110/1110/11/21
Hyatt announced the…
Hyatt announced the opening of IL Tornabuoni Hotel in Florence. The 62-bedroom former palace signifies the debut of The Unbound Collection by Hyatt brand in Italy.
Short Report: Amplify Energy, Lordstown Motors shorts jump amid headwinds » 13:2010/0910/09/21
AMPY, RIDE, FIZZ, M, NYT, AVTE, CRCT, SFIX
Welcome to this week’s…
Bluebird Bio provides update on planned business separation » 16:5710/0810/08/21
Bluebird bio announced…
Bluebird bio announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. SEC. This Form 10 reflects bluebird bio's plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company. The spin-off is on track to be completed by early November. bluebird bio also announced the appointment of Najoh Tita-Reid and Sarah Glickman to the bluebird bio board of directors. Upon effectiveness of the Form 10, Glickman will also be a member of the board of directors of 2seventy bio and will step down from the bluebird bio board of directors upon completion of the spin-off. Upon separation, bluebird bio plans to distribute 100% of the outstanding shares of 2seventy bio common stock to bluebird's shareholders in a 3:1 ratio. For every three shares of bluebird bio stock, current shareholders will receive one share of 2seventy bio stock. The company anticipates that its cash, cash equivalents and marketable securities balance at separation will be approximately $1.0B, inclusive of proceeds from the recent sale of the company's manufacturing facility in North Carolina and its private placement equity financing. bluebird bio expects to fund 2seventy bio with approximately $480M in cash upon separation, with the balance to be retained by bluebird bio. Together with existing and emerging sources of revenue and other anticipated cash inflows, which includes the potential sale of priority review vouchers that would be issued with anticipated U.S. regulatory approvals of BLAs for bluebird's therapies in beta-thalassemia and cerebral adrenoleukodystrophy, the company expects its cash, cash equivalents and marketable securities balance will be sufficient to fund operations for bluebird bio and 2seventy bio into 2023 under current business plans.
Summit Therapeutics appoints Kenneth Clark to board of directors » 08:3110/0810/08/21
Summit Therapeutics announced that Kenneth Clark, JD, has been appointed to our Board of Directors, effective immediately. Mr. Clark is currently a partner at Wilson Sonsini Goodrich & Rosati based out of the firm's Palo Alto, CA, office. In conjunction with Mr. Clark's appointment, Ramses Erdtmann has agreed to make his Summit Board seat available.
Allogene Therapeutics price target lowered to $32 from $41 at BofA » 07:4710/0810/08/21
BofA analyst Jason…
BofA analyst Jason Gerberry lowered the firm's price target on Allogene Therapeutics (ALLO) to $32 from $41 after the company announced a clinical hold was placed on both of its clinical stage allogeneic CAR-T programs after a single patient report involving a chromosomal abnormality in ALLO-501A CAR-T cells in the patient. The clinical hold "creates a layer of regulatory uncertainty," said Gerberry, who noted that it took Bluebird Bio (BLUE) about four months to get a clinical hold removed for its gene therapy for blood disorders to determine whether vector integration promoted cancer. The analyst, who keeps a Buy rating on the shares, said his new target factors in lower clinical probabilities of success for both Allogene programs and reduced assumptions for '501 share versus marketed auto CAR-T's.
FedEx earnings estimates cut below guidance at Citi » 06:5010/0810/08/21
Citi analyst Christian…
Citi analyst Christian Wetherbee lowered his second half of fiscal 2022 earnings estimates for FedEx as he believes it is likely that labor and operational costs from Q1 linger past Q2. He cut his fiscal 2022 earnings per share estimate to $18.85 from $19.75, below the low end of management's $19.75-$21.00 target range. Wetherbee keeps a Buy rating on FedEx with a $300 price target.